View Clinical Trial (Medical Research Study)
Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Cancer
| City: |
|
Bethesda |
| State: |
|
Maryland |
| Zip Code: |
|
20892 |
| Conditions: |
|
Bladder Cancer - Brain and Central Nervous System Tumors - Chordoma - Lung Cancer - Non-melanomatous Skin Cancer - Retinoblastoma - Sarcoma |
| Purpose: |
|
RATIONALE: Studying individuals and families at high risk for cancer may help to identify
other persons at risk and identify cancer genes.
PURPOSE: This clinical trial is studying genetic and environmental factors related to cancer
risk in individuals and families at high risk for cancer.
|
| Study Summary: |
|
OBJECTIVES:
- Identify individuals at high risk of cancer, especially due to personal or family
medical history.
- Evaluate and define clinical spectrum of disease in syndromes predisposing to cancer.
- Quantify risks of tumors in family members.
- Map, clone, and determine function of tumor susceptibility genes.
- Identify genetic determinants and gene-environmental interactions conferring cancer
risk in individuals and families.
- Evaluate gene-gene and gene-environmental interactions in tumor formation.
- Evaluate potential precursor states of disease in families at risk of cancer.
OUTLINE: One family member completes a family history questionnaire for verification of
diagnosis and construction of a family pedigree. Individuals and families undergo clinical
evaluation comprising at least a medical history, physical examination, and testing of blood
specimens. Other biologic specimens may also be obtained from some individuals, and some
individuals may undergo other diagnostic studies and examinations, depending on the type of
familial neoplasm being studied.
If a family is already participating in the study and a specific mutation in a tumor
predisposing gene predictive of disease has already been identified in the family,
individuals may be eligible for genetic testing. Genes tested include RB1, APC, BRCA1/2,
NF2, and VHL. Individuals under age 18 are only eligible to be tested for APC (familial
adenomatous polyposis), NF2 (neurofibromatosis type 2), PTCH (nevoid basal cell carcinoma
syndrome), RB1 (retinoblastoma), and VHL (von Hippel-Lindau disease).
Individuals may receive results of the genetic testing and genetic counseling is offered to
all individuals who are tested.
A certificate of confidentiality protecting the identity of research participants in this
project has been issued by the National Cancer Institute.
Families are followed every 1-2 years. In selected instances, individuals and families may
return to the Clinical Center periodically for study-specific follow-up evaluations.
PROJECTED ACCRUAL: A total of 7,500 individuals will be accrued for this study. Substudies,
involving subsets of the 7,500 individuals, are part of the overall study design.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Family or personal medical history of neoplasia of unusual type, pattern, or number
- Two or more living affected cases among family members are required
- The following types of familial cancers are eligible:
- Bone (non-neuroaxis, such as osteosarcoma)
- Bladder
- Brain
- Chordoma
- Lung
- Nevoid basal cell carcinoma syndrome (NBCC)
- The following type of familial benign neoplasm is eligible:
- Neurofibromatosis type 2 (bilateral acoustic neurofibromatosis) OR
- Known or suspected factor(s) predisposing to neoplasia, meeting 1 of the following
criteria:
- Environmental exposure, including:
- Medications
- Occupation
- Radiation
- Diet
- Infectious agents
- Genetic and/or congenital factors, including:
- Birth defects
- Metabolic phenotype
- Chromosomal anomalies
- Mendelian traits associated with tumors
- Unusual demographic features, including:
- Very young age of onset
- Multiple tumors
- Personal and family medical history must be verified through questionnaires,
interviews, and review of pathology slides and medical records
- Ineligible for familial melanoma, lymphoproliferative, breast-ovarian cancer, or
testicular cancer protocols
PATIENT CHARACTERISTICS:
Age:
- 1 month to 95 years
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Not specified
Other:
- Not pregnant (for parts of protocol involving ionizing radiation or magnetic fields)
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
|
| NCT ID: |
|
NCT00004007 |
| Primary Contact: |
|
Study Chair
Margaret A. Tucker, MD
NCI - Genetic Epidemiology Branch
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Bethesda, Maryland 20892
United States
Patient Recruitment
Phone: 888-NCI-1937
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 24, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|